Labcorp Holdings Inc. logo
Labcorp Holdings Inc. (LH)
Compare

Labcorp Holdings Inc. (LH) EBITDA Margin: 14.43%

Is Labcorp Holdings Inc.’s EBITDA margin high or low?

Labcorp Holdings Inc.'s EBITDA margin of 14.43% is 19% below its 5-year average of 17.86%, near the low end of its 5-year range (11.10%–27.99%).

As of Sunday, June 14, 2026. 1.80% above its 12-month average of 14.18%.

LH EBITDA Margin Chart

LH EBITDA Margin
14.43%+3.66% 1Y
Zoom

LH Average EBITDA Margin Chart

LH Current vs Average EBITDA Margin Chart

LH EBITDA Margin Metrics

EBITDA MARGIN

14.43%

EBITDA MARGIN AVG TTM

14.18%

EBITDA MARGIN AVG 3Y

13.98%

EBITDA MARGIN AVG 5Y

17.86%

EBITDA MARGIN AVG 10Y

18.03%

EBITDA MARGIN AVG 15Y

19.16%

EBITDA MARGIN AVG 20Y

20.26%

CURRENT VS TTM AVG

+1.80%

CURRENT VS 3Y AVG

+3.22%

CURRENT VS 5Y AVG

-19.21%

CURRENT VS 10Y AVG

-19.97%

CURRENT VS 15Y AVG

-24.67%

CURRENT VS 20Y AVG

-28.78%

LH Competitors' EBITDA Margin

NAMEMARKET CAPEBITDA MARGINTTM3Y5Y
Labcorp Holdings Inc. (LH)$21.83B14.43%14.18%13.98%17.86%
Mettler-Toledo International Inc. (MTD)$22.86B30.67%31.14%31.31%30.59%
BioNTech SE (BNTX)$22.90B-22.78%-18.06%18.90%22.14%
United Therapeutics Corporation (UTHR)$23.17B57.15%57.33%56.99%52.54%
Waters Corporation (WAT)$23.17B31.97%33.50%33.77%33.93%
Moderna, Inc. (MRNA)$19.80B-131.33%-118.72%-58.16%-40.65%
Veeva Systems Inc. (VEEV)$25.92B37.38%36.14%30.88%30.08%
Hologic, Inc. (HOLX)$16.97B24.97%28.56%32.04%36.42%
DexCom, Inc. (DXCM)$29.08B29.14%26.30%24.33%22.05%
Biogen Inc. (BIIB)$29.53B31.60%31.28%30.38%32.54%

Margin Comparison

Gross Margin

27.8%

EBITDA Margin

14.4%

Operating Margin

11.0%

Net Margin

6.7%

Formula: EBITDA Margin = (EBITDA / Revenue) × 100

Why EBITDA Margin matters:

  • Removes effects of depreciation policies (D&A)
  • Capital structure neutral (ignores interest)
  • Tax neutral (ignores tax differences)
  • Good proxy for operating cash generation

Labcorp Holdings Inc. EBITDA Margin Formula & Definition

EBITDA Margin = EBITDA / Revenue

EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Labcorp Holdings Inc. EBITDA Margin FAQ

What is the EBITDA margin for Labcorp Holdings Inc. (LH)?
The EBITDA margin for LH stock is 14.43%.
Is Labcorp Holdings Inc.'s EBITDA margin high or low?
Labcorp Holdings Inc.'s EBITDA margin of 14.43% is 19% below its 5-year average of 17.86%, near the low end of its 5-year range (11.10%–27.99%).
What is the TTM average EBITDA margin for Labcorp Holdings Inc. (LH)?
The TTM average EBITDA margin for LH stock is 14.18%.
What is the 3Y average EBITDA margin for Labcorp Holdings Inc. (LH)?
The 3Y average EBITDA margin for LH stock is 13.98%.
What is the 5Y average EBITDA margin for Labcorp Holdings Inc. (LH)?
The 5Y average EBITDA margin for LH stock is 17.86%.
What is the 10Y average EBITDA margin for Labcorp Holdings Inc. (LH)?
The 10Y average EBITDA margin for LH stock is 18.03%.
What is the 15Y average EBITDA margin for Labcorp Holdings Inc. (LH)?
The 15Y average EBITDA margin for LH stock is 19.16%.
What is the 20Y average EBITDA margin for Labcorp Holdings Inc. (LH)?
The 20Y average EBITDA margin for LH stock is 20.26%.

Labcorp Holdings Inc. EBITDA Margin History

DATEEBITDA MARGIN
2025-12-3114.43%
2024-12-3113.92%
2023-12-3111.10%
2022-12-3116.47%
2021-12-3127.99%
2020-12-3123.26%
2019-12-3118.32%
2018-12-3118.22%
2017-12-3117.68%
2016-12-3118.77%
2015-12-3118.17%
2014-12-3119.56%
2013-12-3121.32%
2012-12-3122.21%
2011-12-3121.31%
2010-12-3123.77%
2009-12-3124.30%
2008-12-3122.99%
2007-12-3124.34%
2006-12-3123.76%
2005-12-3123.58%
2004-12-3125.62%
2003-12-3122.74%
2002-12-3122.10%
2001-12-3121.44%
2000-12-3117.70%
1999-12-3113.79%
1998-12-3113.13%
1997-12-311.15%
1996-12-3111.61%

About Labcorp Holdings Inc.

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.

Burlington, NC
60,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Adam H. Schechter